Medical devices, healthcare technology and the business of care
PMA approval · P110019

Xience Skypoint Everolimus Eluting Coronary Stent System

Abbott Vascular · Decision date Nov 1, 2011

MEDTECHLEDGER EXPLANATIONP110019

What did the FDA approve?

The FDA database entry for P110019 records an original PMA approval dated November 1, 2011, for the Xience Prime and Xience Prime LL Everolimus Eluting Coronary Stent System. The stated purpose is improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions of length 32 mm or less, with reference vessel diameters from 2.25 mm to 4.25 mm.

The entry lists Abbott Vascular as the applicant and classifies the device under product code NIQ as a coronary drug-eluting stent in the cardiovascular specialty. No supplement type or supplement reason is recorded, so the decision reflects the original approval scope rather than a later change. The source statement reports an indicated use but does not itself provide independent proof of safety or clinical effectiveness.

FDA approval order statement

APPROVAL FOR THE XIENCE PRIME AND XIENCE PRIME LL EVEROLIMUS ELUTING CORONARY STENT SYSTEM. THIS DEVICE IS INDICATED FOR IMPROVING CORONARY LUMINAL DIAMETER IN PATIENTS WITH SYMPTOMATIC HEART DISEASE DUE TO DE NOVO NATIVE CORONARY ARTERY LESIONS (LENGTH <= 32 MM) WITH REFERENCE VESSEL DIAMETERS OF >= 2.25 MM TO <= 4.25 MM.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Nov 1, 2011

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P110019
Regulatory pathway
Premarket approval application
Product code
NIQ
Decision code
APPR
Decision date
Nov 1, 2011
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Product code
NIQ
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P110019 received

    Application receipt date recorded by FDA.

  2. P110019 · FDA decision

    APPR

  3. P110019/S145 · Related supplement

    XIENCE PRO5 Everolimus Eluting Coronary Stent System (XIENCE PRO5), XIENCE Skypoint Everolimus Eluting Coronary Stent Sy

Timeline entries are records held by MedtechLedger for P110019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P110019

Product / regulatory recordCompanyPathwayDecision dateSource
Abbott VascularPMA supplementOct 1, 2026FDA

Explore the linked device profile

Other records with product code NIQ

Product / regulatory recordCompanyPathwayDecision dateSource
Medtronic VascularPMA supplementOct 16, 2026FDA
Biotronik AGPMA supplementSep 24, 2026FDA
Biotronik AGPMA approvalFeb 22, 2019FDA
Medtronic VascularPMA approvalApr 28, 2017FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abbott Vascular

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
3200 Lakeside Dr., Santa Clara, CA, 95054

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records